Jade Biosciences, Inc.
JBIO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$14.59
KIRA · Stoqly’s AI analyst, in plain words
- Jade Biosciences, Inc. lost $127M in fiscal 2025.
- Free cash flow was −$94.9M in fiscal 2025, — of revenue.
Market cap
$891M
P/E
1.7x
Revenue
—
Net income
−$127M
Free cash flow
−$94.9M
Operating margin
—
Jade Biosciences, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$127M
No. It lost money last year.
How is the share priced?
1.7x
One share costs 1.7 times its yearly profit per share.
What Jade Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 6, 2026
- Legal name
- Jade Biosciences, Inc.
- CIK
- 0001798749
Jade Biosciences, Inc. · JBIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$23.0M | −$51.5M | −$75.5M | −$69.6M | −$127M |
| Diluted EPS | −$1.87 | −$2.10 | −$2.87 | −$2.44 | −$3.19 |
| Cash | |||||
| Cash from operations | −$27.4M | −$39.1M | −$56.8M | −$71.2M | −$94.7M |
| Capital expenditure | $0.2M | $0.2M | $0.1M | — | $0.2M |
| Free cash flow | −$27.6M | −$39.3M | −$56.9M | — | −$94.9M |
| Share count change | 4,975.8% | 99.1% | 7.6% | 8.5% | 9.7% |
| Debt and strength | |||||
| Cash and short-term investments | $167M | $129M | $122M | $69.4M | $336M |
| Shareholders' equity | $172M | $127M | $109M | −$46.8M | $333M |
| Current ratio | 68.4x | 16.9x | 7.0x | 5.8x | 21.1x |
| Returns and quality | |||||
| Return on equity | −28.9% | −34.4% | −63.9% | −222.3% | −89.2% |
| Return on tangible equity | −13.3% | −40.6% | −69.0% | — | −30.1% |
| Altman Z'' | 66.3 | 16.8 | 3.4 | −4.2 | 22.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Jade Biosciences, Inc. · JBIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $14.59 a share, the company is worth $891M: 1.7 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001798749). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.